AstraZeneca: Zegfrovy Now Available in the U.S. for Patients With Previously Treated Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
October 23, 2026
October 23, 2026
WILMINGTON, Delaware, Oct. 23 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
ZEGFROVY(R) (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations
22 October 2026
Only approved oral, single agent, targeted therapy for these patients following platinum-based chemotherapy
Launch expands AstraZeneca's commitm . . .
* * *
ZEGFROVY(R) (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations
22 October 2026
Only approved oral, single agent, targeted therapy for these patients following platinum-based chemotherapy
Launch expands AstraZeneca's commitm . . .